College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
Center for Paralysis Research & Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA.
Transl Neurodegener. 2021 Apr 28;10(1):13. doi: 10.1186/s40035-021-00239-0.
The mechanisms underlying lesions of dopaminergic (DA) neurons, an essential pathology of Parkinson's disease (PD), are largely unknown, although oxidative stress is recognized as a key factor. We have previously shown that the pro-oxidative aldehyde acrolein is a critical factor in PD pathology, and that acrolein scavenger hydralazine can reduce the elevated acrolein, mitigate DA neuron death, and alleviate motor deficits in a 6-hydroxydopamine (6-OHDA) rat model. As such, we hypothesize that a structurally distinct acrolein scavenger, dimercaprol (DP), can also offer neuroprotection and behavioral benefits.
DP was used to lower the elevated levels of acrolein in the basal ganglia of 6-OHDA rats. The acrolein levels and related pathologies were measured by immunohistochemistry. Locomotor and behavioral effects of 6-OHDA injections and DP treatment were examined using the open field test and rotarod test. Pain was assessed using mechanical allodynia, cold hypersensitivity, and plantar tests. Finally, the effects of DP were assessed in vitro on SK-N-SH dopaminergic cells exposed to acrolein.
DP reduced acrolein and reversed the upregulation of pain-sensing transient receptor potential ankyrin 1 (TRPA1) channels in the substantia nigra, striatum, and cortex. DP also mitigated both motor and sensory deficits typical of PD. In addition, DP lowered acrolein and protected DA-like cells in vitro. Acrolein's ability to upregulate TRPA1 was also verified in vitro using cell lines.
These results further elucidated the acrolein-mediated pathogenesis and reinforced the critical role of acrolein in PD while providing strong arguments for anti-acrolein treatments as a novel and feasible strategy to combat neurodegeneration in PD. Considering the extensive involvement of acrolein in various nervous system illnesses and beyond, anti-acrolein strategies may have wide applications and broad impacts on human health.
帕金森病(PD)的一个重要病理学特征是多巴胺能(DA)神经元的损伤,但损伤的机制尚不清楚,尽管氧化应激被认为是一个关键因素。我们之前已经表明,促氧化醛丙烯醛是 PD 病理学的一个关键因素,丙烯醛清除剂Hydralazine 可以降低升高的丙烯醛水平,减轻 DA 神经元死亡,并在 6-羟多巴胺(6-OHDA)大鼠模型中减轻运动缺陷。因此,我们假设结构不同的丙烯醛清除剂二巯丁二钠(DP)也可以提供神经保护和行为益处。
用二巯丁二钠(DP)降低 6-OHDA 大鼠基底节中升高的丙烯醛水平。通过免疫组织化学法测量丙烯醛水平和相关病理。使用旷场试验和转棒试验检测 6-OHDA 注射和 DP 治疗的运动和行为效应。使用机械性痛觉过敏、冷敏感和足底试验评估疼痛。最后,在体外评估 DP 对暴露于丙烯醛的 SK-N-SH 多巴胺能细胞的作用。
DP 降低了丙烯醛水平,并逆转了黑质、纹状体和皮质中疼痛感觉瞬时受体电位锚蛋白 1(TRPA1)通道的上调。DP 还减轻了 PD 典型的运动和感觉缺陷。此外,DP 降低了丙烯醛并保护了体外的 DA 样细胞。在体外使用细胞系也验证了丙烯醛上调 TRPA1 的能力。
这些结果进一步阐明了丙烯醛介导的发病机制,并强化了丙烯醛在 PD 中的关键作用,同时为抗丙烯醛治疗作为一种新的可行策略来对抗 PD 中的神经退行性变提供了有力论据。考虑到丙烯醛在各种神经系统疾病中的广泛参与,甚至超越了神经系统疾病,抗丙烯醛策略可能具有广泛的应用和对人类健康的广泛影响。